Healthcare Professionals

Clinical Rationale for Metabo Age

This page is intended for registered healthcare professionals considering Metabo Age™ as part of a structured metabolic wellness protocol. It summarises the published evidence base for each ingredient, presents key clinical data, and provides a direct channel for professional enquiries and account registration.

Metabo Age™ is a health supplement. It is not a medicine and is not intended to diagnose, treat, cure, or prevent any disease. Clinical data referenced below relates to individual ingredients as studied in published peer-reviewed trials, not to the Metabo Age formulation as a whole.

Key Ingredient Evidence

Urolithin A — Published Clinical Outcomes

Data from Singh et al. (2022), Cell Reports Medicine. Double-blind, placebo-controlled RCT. n=88 healthy middle-aged adults (40–64 years). Duration: 4 months. Doses: 500mg/day and 1,000mg/day vs placebo.

Source: Singh A, et al. Cell Rep Med. 2022;3(5):100633. doi:10.1016/j.xcrm.2022.100633

Skeletal Muscle Strength — % Change from Baseline vs Placebo

Average peak torque improvement at 4 months. Hamstring and knee flexion measurements.

PlaceboUA 500mgUA 1000mg+0%+4%+8%+12%+16%
  • Hamstring Strength
  • Knee Flexion Strength

Muscle Endurance — Cumulative Improvement Over 4 Months (%)

Illustrative trajectory based on published trial data. Endurance measured by isometric fatigue testing.

Baseline2 Months4 Months+0%+4%+8%+14%
  • Placebo
  • UA 500mg
  • UA 1000mg

Mitochondrial & Inflammatory Biomarkers — Relative Improvement (%)

Skeletal muscle biopsies and plasma analysis. UA 500mg vs placebo at 4 months. Relative change from baseline.

Mitochondrial Gene ExpressionPlasma AcylcarnitinesInflammatory Markers+0%+9%+18%+35%
  • Placebo
  • UA 500mg

Note: Biomarker data are illustrative of relative directional trends reported in Singh et al. (2022). Absolute values vary by biomarker. Refer to the original publication for full statistical analysis.

Formulation Rationale

Ingredient-by-Ingredient Evidence Summary

Dose per Capsule

250 mg per capsule

Mechanism of Action

Urolithin A is a postbiotic metabolite produced by gut microbiota from ellagitannins found in pomegranate and berries. It is the only compound clinically demonstrated to activate mitophagy — the selective clearance of dysfunctional mitochondria — in human skeletal muscle. By promoting mitochondrial quality control, it supports the maintenance of cellular energy production capacity as the body ages.

Evidence Summary

Singh et al. (2022), Cell Reports Medicine. Double-blind, placebo-controlled RCT, n=88, ages 40–64, 4 months. 500mg/day: +12% hamstring strength, +10.6% knee flexion strength vs placebo. Significant improvements in mitochondrial gene expression biomarkers in skeletal muscle biopsies.

Primary Reference

Singh A, et al. Cell Rep Med. 2022;3(5):100633. doi:10.1016/j.xcrm.2022.100633

View on PubMed →

Clinical Context

Urolithin A is the anchor ingredient in the Metabo Age formulation. Its clinical evidence base is the strongest of any mitophagy-activating compound in human supplementation.

Full Formulation — Per Serving (2 Capsules)

IngredientAmount per ServingPrimary RoleKey Reference
Urolithin A500 mgMitophagy activation, mitochondrial quality controlSingh et al., Cell Rep Med, 2022
Alpha-Lipoic Acid700 mgMitochondrial cofactor, antioxidant supportPacker et al., Free Radic Biol Med, 1995
Magnesium Glycinate200 mgATP synthesis cofactor, enzymatic supportBarbagallo & Dominguez, Mol Aspects Med, 2010
Chromium Picolinate400 mcgInsulin signalling, glucose metabolism supportBroadhurst & Domenico, Diabetes Technol Ther, 2006

Capsule shell: plant-derived (HPMC). No artificial colours, flavours, or preservatives. Suitable for vegetarians. Manufactured by FinLab. Store below 25°C, away from direct sunlight and moisture.

Professional Account

Register a Professional Enquiry

For clinic supply, patient recommendation accounts, wholesale pricing, or clinical protocol integration, please complete the form below. Our clinical team will respond within two business days.

Your enquiry will be handled by the Metabo Age clinical team. Information provided will be used solely for the purpose of responding to your enquiry and will not be shared with third parties.